Ignite Creation Date:
2024-05-05 @ 11:19 PM
Last Modification Date:
2024-10-26 @ 10:31 AM
Study NCT ID:
NCT01300429
Status:
COMPLETED
Last Update Posted:
2021-01-07
First Post:
2011-02-17
Brief Title:
Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to try to learn more about how small molecule kinase inhibitor medications work in treating lung cancer Crizotinib PF-02341066 is a drug that has been shown to shrink tumors in some patients with lung cancer While the investigators know how this drug works to stop the growth of tumors that depend on change in the gene named ALK also called EML4-ALK the investigators do not know why the drug stops working The investigators would like to examine the tumor to help us better understand why crizotinib has stopped working as well as it once did The tumor will be examined with multiple tests to look for the reason that crizotinib stopped working
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None